Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group

Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group

Background: In node-negative breast cancer (NNBC), a high risk of recurrence is determined by clinico-pathological or tumor-biological assessment. Taxanes may improve adjuvant chemotherapy. Methods: NNBC 3-Europe, the first randomized phase-3 trial in node-negative breast cancer (BC) with tumor-biol...

Full description

Bibliographic Details
Main Authors: Christoph Thomssen, Martina Vetter, Eva J. Kantelhardt, Christoph Meisner, Marcus Schmidt, Pierre M. Martin, Florian Clatot, Doris Augustin, Volker Hanf, Daniela Paepke, Wolfgang Meinerz, Gerald Hoffmann, Wolfgang Wiest, Fred C. G. J. Sweep, Manfred Schmitt, Fritz Jänicke, Sibylle Loibl, Gunter von Minckwitz, Nadia Harbeck
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
node-negative breast cancer
uPA/PAI-1
adjuvant chemotherapy
docetaxel
Online Access:https://www.mdpi.com/2072-6694/15/5/1580

Similar Items

Similar Items